Inventiva (IVA) Appoints Renée Aguiar-Lucander to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- S&P 500 muted as industrials counter tech drag; US-Iran peace prospects rise
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors
June 10, 2025 4:00 PM EDTDaix (France), New York City (New York, United States), June 10, 2025 Inventiva (Euronext Paris and Nasdaq: IVA) (Inventiva or the Company), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), today announced the appointment of Renée Aguiar-Lucander to its Board of Directors. The appointment was approved by shareholders at the recent Companys Annual General Meeting.
Mark Pruzanski, Chairman of Inventiva: We are thrilled to welcome Renée to the Board at this pivotal moment in Inventivas journey.... More
